Suppliers / Hospira

Hospira

United States Updated 9 July 2026

Hospira is a finished-dose manufacturer based in United States. It holds 2 active US drug master files across a filed portfolio of 2 molecules. Its filings concentrate with US FDA, AIFA (IT) and FAMHP (BE). Its GMP standing is certified by MFDS (Korea), EAEU_EEC and ANVISA (Brazil), among 7 authorities. Its most recent recorded inspection, by US FDA, closed on 7 February 2025 as NAI.

2
active US DMFs
0
valid CEPs
12
registered plants
5,863
filings across 41 regulators
These figures were checked against the regulators' own files on 25 July 2026
Inspections
0 of 8 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 7 February 2025 NAI US FDA
  • 17 January 2025 VAI US FDA
  • 27 March 2024 NAI US FDA
  • 17 January 2020 VAI US FDA
  • 21 November 2019 VAI US FDA
  • 15 August 2018 OAI US FDA
  • 2 February 2018 VAI US FDA
  • 27 October 2017 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
McPherson, United Arab Emirates Not on file
Rocky Mount, United Arab Emirates Not on file
Ascoli Piceno (AP), United Arab Emirates Not on file
Kalamazoo, United Arab Emirates Not on file
Ascoli Piceno (AP), United Arab Emirates Not on file
Kalamazoo, United Arab Emirates Not on file

6 further sites are on record.

What they file, and where

Molecule Regulators Docs
Isoprenaline US FDA 1
Vancomycin US FDA 1

Also appears on these molecule pages

Acetylcysteine finished dose Acetylsalicylic Acid finished dose Acyclovir finished dose Ampicillin finished dose Azithromycin finished dose Cabergoline finished dose Calcitriol finished dose Carboplatin finished dose Ceftriaxone finished dose Cefuroxime finished dose Ciprofloxacin finished dose Clindamycin finished dose
Show 42 more molecule pages
Daptomycin finished dose Diazepam finished dose Digoxin finished dose Diltiazem finished dose Diphenhydramine finished dose Doxycycline finished dose Ertapenem finished dose Erythromycin finished dose Famotidine finished dose Fluconazole finished dose Furosemide finished dose Gentamicin finished dose Haloperidol finished dose Heparin finished dose Hydrocortisone finished dose Hydroxyzine finished dose Indomethacin finished dose Ketorolac Tromethamine finished dose Levofloxacin finished dose Lidocaine finished dose Lorazepam finished dose Meropenem finished dose Methylprednisolone finished dose Metoclopramide finished dose Metoprolol finished dose Midazolam finished dose Ondansetron finished dose Paclitaxel finished dose Phenobarbital finished dose Phenytoin finished dose Piperacillin finished dose Propofol finished dose Rivaroxaban finished dose Sulbactam finished dose Sulfamethoxazole finished dose Tacrolimus finished dose Tazobactam finished dose Tobramycin finished dose Trimethoprim finished dose Valproic Acid finished dose Verapamil finished dose Vildagliptin finished dose

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA 716 2
AIFA (IT) 653 None
FAMHP (BE) 611 None
EMA 436 None
INHRR (VE) 333 None
URPL (PL) 312 None
MFDS (Korea) None 6
EAEU_EEC None 6
ANVISA (Brazil) None 6
HSA (SG) None 4
MHRA (UK) None 2
NAFDAC (NG) None 2

Comparing suppliers?

Choose your molecules and target markets. Hospira comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • 81 active litigation matters are on record.
  • The most recent inspection outcome was NAI, on 7 February 2025.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates